GlassScriptPhysician profile
Barbra Janis Restorick
NPI 1871966838
$6,559.32
in general payments reported to CMS, 2019-2025
26 companies · $855 in 2025
The $855 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $884 · 2022: $1,947 · 2023: $1,707 · 2024: $1,165 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,713 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,713.11 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,862.61 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $870.47 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $404.57 | 2021-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $395.63 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $343.49 | 2021-2023 | Rexulti |
| Indivior INC. | $301.43 | 2024-2025 | Sublocade |
| Axsome Therapeutics, INC. | $277.94 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $254.27 | 2021-2023 | Ingrezza |
| Alkermes, INC. | $243.70 | 2021-2023 | Lybalvi, Vivitrol |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $205.82 | 2022-2024 | |
| Amgen INC. | $169.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $124.99 | 2023 | Quviviq |
| Urovant Sciences INC | $124.99 | 2022 | |
| Emd Serono, INC. | $124.99 | 2023 | |
| Gilead Sciences, INC. | $122.14 | 2022-2023 | Epclusa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $120.87 | 2024 | Brixadi |
| Jazz Pharmaceuticals INC. | $92.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $87.97 | 2022 | |
| Lilly USA, LLC | $85.35 | 2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $63.39 | 2022 | |
| Ironshore Pharmaceuticals INC. | $63.28 | 2022 | |
| Vanda Pharmaceuticals INC. | $57.25 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $57.14 | 2021 | |
| Amneal Pharmaceuticals LLC | $51.86 | 2022 | |
| Orexo US, INC. | $34.82 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbra Restorick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.